Backs the full SELL: a record-volume red candle at resistance, a one-time passive flow event that already happened, and a hawkish macro tape are a gift, not a reason to hold. The reward/risk to the upper band vs. the support confluence is roughly 1:2 against you.
Wants exposure cut to ~50% of a standard allocation now, stop at $158.5 on a confirmed close, and the re-entry opportunity saved for below the 200-day SMA once the multiple compresses and weak hands are shaken out.
Agrees the direction is right — trim into strength, since the rebalance catalyst is spent and the reward/risk skews negative — but calls the aggressive $158.5 intraday stop too tight (~0.78x ATR) given a 6.67-point daily range; wants a close-based invalidation instead.
Proposes scaling out in tranches ($153.5–155, then $156–157) down to roughly half weight, keeping a 20–25% residual stub, with $145.30 then $142.79 as the downside structural exits.
Doesn't dispute the resistance and macro concerns but argues the fundamental inflection — positive EBIT, +$2.4B OCF, ~$60B net cash, $14.3B deferred revenue — and the intact moving-average trend structure don't justify cutting the position in half.
Prefers trimming to 70–80% of a standard allocation with a structural stop at $145.30 (the 20 SMA/Bollinger mid), arguing an intraday stop at $158.5 all but guarantees a whipsaw loss before the golden cross can complete.
Thesis: the debate converged on a trim, not an exit. Even the Aggressive analyst's "Sell" is operationally a reduction to ~50% with a residual stub; the Conservative defends 70–80%; the Neutral lands at half weight with a 20–25% stub — a consensus for "reduce exposure, take partial profits." The bear case decides the direction: at ~87x trailing sales and 87.6x forward earnings against a TTM net loss of -$8.9B, the price already underwrites a ~$32B swing to profitability, Q2's positive EBIT doesn't cover the quarterly interest bill, the ~$60B net cash position is a six-quarter runway bought with heavy dilution (not a solved funding story), and on the largest-volume day in the stock's public life — boosted by a one-time forced Nasdaq-100 rebalance bid — SPCX still closed red under the $157.11 upper band, leaving organic demand unproven. Near-term asymmetry is negative (+2.8% to resistance vs. -5% to support) and the macro backdrop (86% odds of another hike, 96% odds of no cuts) is hostile to this high-duration asset. What caps the reduction at half weight instead of zero: the fundamental inflection is real and effectively uncontested — Q2 revenue +92% YoY, gross margin +11pts to 55.3%, EBITDA nearly tripled, OCF turned positive, $14.3B of deferred revenue, and 26-of-34 analyst Buy ratings, with price still above every major moving average and the golden cross pending rather than failed.
Action: scale out in tranches into the $153.5–157.11 supply zone (first piece $153.5–155, second $156–157 if offered) down to roughly half a standard allocation, keeping a residual stub of 20–25% of the original position; do not initiate new longs at $150–153. Risk control is close-based, not an intraday stop: a daily close above $157.11 (confirmed at $158.5) invalidates the trim thesis and lets the stub run, while a sustained break of $145.30 cuts most of the residual and the 200-day at $142.79 is the final exit, with no averaging down. Horizon is 1–2 quarters with Q3 earnings as the single validation event; re-adding toward Hold/Overweight requires at least two of: Q3 confirming Q2's growth with improved GAAP/FCF, an organic-volume breakout above $157.11 with MACD re-expansion, or the 50-day crossing above the 200-day. Downgrade to Sell on a sustained break of $145.30 then $142.79, Q3 growth reverting to Q1's pace, or another large dilutive raise.